The closing of the dilutive US offering at a 26% discount confirms immediate selling pressure. The upcoming shareholder meeting on September 11, 2026, for approval of additional tranches (Australian Placement and SPP) introduces further dilution risk. Monitor for any clinical data catalysts (RAD101 Phase 3 readiness) that could offset the overhang, but the capital structure deterioration is the dominant near-term factor.
Price Chart
Executive Summary
Radiopharm Theranostics filed a 6-K on July 28, 2026, confirming the closing of its previously announced US$4.1 million registered direct offering of 1,281,646 ADSs at US$3.16 per ADS, alongside a concurrent private placement of warrants exercisable at US$3.79 per ADS. The filing also details a multi-tranche capital raise including an Australian Placement (A$6.7M) and a Share Purchase Plan (up to A$6M), with proceeds earmarked for clinical programs including a registrational Phase 3 study for RAD101. The combination of a dilutive offering at a ~26% discount to the prior close and the need for shareholder approval for additional tranches signals significant capital urgency for this pre-revenue biotech, reinforcing the bearish read from the prior day's 424B5 filing.
Key Facts
- Closed registered direct offering of 1,281,646 ADSs at US$3.16 per ADS for gross proceeds of ~US$4.1 million.
- Concurrent private placement of warrants to purchase up to 1,281,646 ADSs at US$3.79 per ADS, expiring July 31, 2029.
- Additional capital raise includes A$6.7 million (US$4.7M) Australian Placement and up to A$6 million (US$4.2M) Share Purchase Plan, both subject to shareholder approval.
- Proceeds to fund RAD101 registrational Phase 3 study, RAD 204 dose escalation, and other pipeline programs.
- Shareholder meeting for approvals expected on or about September 11, 2026.
Financial Impact
Total capital raise of approximately US$13M+ (US$4.1M US offering + US$4.7M Australian Placement + up to US$4.2M SPP) against a ~$47M market cap, representing ~28%+ potential dilution.
Risk Factors
- Significant dilution from multiple concurrent capital raises (US offering + Australian Placement + SPP) totaling >$10M against a ~$47M market cap.
- Shareholder approval required for key tranches introduces execution risk and timeline uncertainty.
- Pre-revenue clinical-stage biotech with no approved products; cash burn dependent on successful fundraising.
- Warrant overhang (1.28M ADSs at US$3.79) could pressure stock if exercised.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (RADX) — Batch item 1 | 0001213900-26-082101 |
| Document: ea0299455-6k_radiopharm.htm | 0001213900-26-082101 |
| Document: 0001213900-26-082101-index-headers.html | 0001213900-26-082101 |
| Document: 0001213900-26-082101-index.html | 0001213900-26-082101 |
| Document: 0001213900-26-082101.txt | 0001213900-26-082101 |
| 6-K Filing (RADX) — Batch item 6 | 0001213900-26-082101 |
| Document: ea0299455-6k_radiopharm.htm | 0001213900-26-082101 |
| Document: 0001213900-26-082101-index-headers.html | 0001213900-26-082101 |
| Document: 0001213900-26-082101-index.html | 0001213900-26-082101 |
| Document: 0001213900-26-082101.txt | 0001213900-26-082101 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9600 | awaiting T+5 | — | $0.9000 (−6.25%) |
Oct 26, 2026 1d ago | 6-K | $0.9960 | awaiting T+5 | — | $0.9000 (−9.64%) |
Oct 20, 2026 7d ago | 6-K | $0.9900 $0.9000 | ▼ −9.09% | ▼ −9.17% | $0.9000 (−9.09%) |
Oct 14, 2026 13d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9000 (−16.67%) |
Oct 5, 2026 22d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9000 (−29.13%) |
Oct 1, 2026 26d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9000 (−39.19%) |
Sep 30, 2026 27d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9000 (−44.44%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9000 (+42.74%) |
Sep 22, 2026 5w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9000 (−45.45%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9000 (−55.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers